TY - JOUR
T1 - Point-of-care oral cytology tool for the screening and assessment of potentially malignant oral lesions
AU - McRae, Michael P.
AU - Modak, Sayli S.
AU - Simmons, Glennon W.
AU - Trochesset, Denise A.
AU - Kerr, A. Ross
AU - Thornhill, Martin H.
AU - Redding, Spencer W.
AU - Vigneswaran, Nadarajah
AU - Kang, Stella K.
AU - Christodoulides, Nicolaos J.
AU - Murdoch, Craig
AU - Dietl, Steven J.
AU - Markham, Roger
AU - McDevitt, John T.
N1 - Funding Information:
Funding for this work was provided by the National Institutes of Health through the National Institute of Dental and Craniofacial Research (awards 1RC2DE020785-01, 5RC2DE020785-02, 3RC2DE020785-02S1, 3RC2DE020785-02S2, 4R44DE025798-02, and R01DE024392). The content of this article is solely the responsibility of the authors and does not necessarily represent or reflect the official views of the National Institutes of Health or the US government. Segments of this work were supported by Renaissance Health Service Corporation and Delta Dental of Michigan.
Funding Information:
Michael P. McRae has served as paid consultant for SensoDx and has a provisional patent pending. Glennon W. Simmons has patents US10060937B2 and US7781226B2 issued. Denise A. Trochesset has received grants from the New York University College of Dentistry for work performed as part of the current study. Martin H. Thornhill has received National Institutes of Health grant 1RC2DE020785‐01 for work performed as part of the current study. Spencer W. Redding has patent US9535068B2 issued. Stella K. Kang has received royalties from Wolters Kluwer for work performed outside of the current study. John T. McDevitt has received grants from the National Institutes of Health for work performed as part of the current study (grants 1RC2DE020785‐01, 4R44DE025798‐02, and R01DE024392) and has a provisional patent pending. In addition, he has an ownership position and an equity interest in SensoDx II LLC and also serves on its Scientific Advisory Board. The other authors made no disclosures.
Funding Information:
Funding for this work was provided by the National Institutes of Health through the National Institute of Dental and Craniofacial Research (awards 1RC2DE020785‐01, 5RC2DE020785‐02, 3RC2DE020785‐02S1, 3RC2DE020785‐02S2, 4R44DE025798‐02, and R01DE024392). The content of this article is solely the responsibility of the authors and does not necessarily represent or reflect the official views of the National Institutes of Health or the US government. Segments of this work were supported by Renaissance Health Service Corporation and Delta Dental of Michigan.
Publisher Copyright:
© 2020 The Authors. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Background: The effective detection and monitoring of potentially malignant oral lesions (PMOL) are critical to identifying early-stage cancer and improving outcomes. In the current study, the authors described cytopathology tools, including machine learning algorithms, clinical algorithms, and test reports developed to assist pathologists and clinicians with PMOL evaluation. Methods: Data were acquired from a multisite clinical validation study of 999 subjects with PMOLs and oral squamous cell carcinoma (OSCC) using a cytology-on-a-chip approach. A machine learning model was trained to recognize and quantify the distributions of 4 cell phenotypes. A least absolute shrinkage and selection operator (lasso) logistic regression model was trained to distinguish PMOLs and cancer across a spectrum of histopathologic diagnoses ranging from benign, to increasing grades of oral epithelial dysplasia (OED), to OSCC using demographics, lesion characteristics, and cell phenotypes. Cytopathology software was developed to assist pathologists in reviewing brush cytology test results, including high-content cell analyses, data visualization tools, and results reporting. Results: Cell phenotypes were determined accurately through an automated cytological assay and machine learning approach (99.3% accuracy). Significant differences in cell phenotype distributions across diagnostic categories were found in 3 phenotypes (type 1 [“mature squamous”], type 2 [“small round”], and type 3 [“leukocytes”]). The clinical algorithms resulted in acceptable performance characteristics (area under the curve of 0.81 for benign vs mild dysplasia and 0.95 for benign vs malignancy). Conclusions: These new cytopathology tools represent a practical solution for rapid PMOL assessment, with the potential to facilitate screening and longitudinal monitoring in primary, secondary, and tertiary clinical care settings.
AB - Background: The effective detection and monitoring of potentially malignant oral lesions (PMOL) are critical to identifying early-stage cancer and improving outcomes. In the current study, the authors described cytopathology tools, including machine learning algorithms, clinical algorithms, and test reports developed to assist pathologists and clinicians with PMOL evaluation. Methods: Data were acquired from a multisite clinical validation study of 999 subjects with PMOLs and oral squamous cell carcinoma (OSCC) using a cytology-on-a-chip approach. A machine learning model was trained to recognize and quantify the distributions of 4 cell phenotypes. A least absolute shrinkage and selection operator (lasso) logistic regression model was trained to distinguish PMOLs and cancer across a spectrum of histopathologic diagnoses ranging from benign, to increasing grades of oral epithelial dysplasia (OED), to OSCC using demographics, lesion characteristics, and cell phenotypes. Cytopathology software was developed to assist pathologists in reviewing brush cytology test results, including high-content cell analyses, data visualization tools, and results reporting. Results: Cell phenotypes were determined accurately through an automated cytological assay and machine learning approach (99.3% accuracy). Significant differences in cell phenotype distributions across diagnostic categories were found in 3 phenotypes (type 1 [“mature squamous”], type 2 [“small round”], and type 3 [“leukocytes”]). The clinical algorithms resulted in acceptable performance characteristics (area under the curve of 0.81 for benign vs mild dysplasia and 0.95 for benign vs malignancy). Conclusions: These new cytopathology tools represent a practical solution for rapid PMOL assessment, with the potential to facilitate screening and longitudinal monitoring in primary, secondary, and tertiary clinical care settings.
KW - artificial intelligence
KW - biomarkers
KW - cytology
KW - oral epithelial dysplasia
KW - point-of-care testing
KW - single-cell analysis
KW - squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85079160493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079160493&partnerID=8YFLogxK
U2 - 10.1002/cncy.22236
DO - 10.1002/cncy.22236
M3 - Article
C2 - 32032477
AN - SCOPUS:85079160493
SN - 1934-662X
VL - 128
SP - 207
EP - 220
JO - Cancer Cytopathology
JF - Cancer Cytopathology
IS - 3
ER -